Cadila Healthcare Limited engages in the research, development, production, marketing, and distribution of pharmaceutical products. Its product portfolio includes active pharmaceutical ingredients and human formulations. The company offers branded formulations in the therapeutic areas of neurological, neutraceutical, pain management, gastro intestinal, respiratory, anti-infective, biological, cardiovascular, female healthcare, dermatology, and others. It also provides consumer wellness products, such as Sugar Free, a low calorie sugar substitute; EverYuth, a range of skincare products; and Nutralite, a cholesterol free table spread. In addition, the company is developing a pipeline of 20 biologics comprising 14 biosimilars and 6 novel biological products; and new drugs in cardio-metabolic disorder, inflammation, pain, and oncology therapeutic areas. Further, it provides animal healthcare products. Additionally, the company is developing vaccines that are designed to address infectious diseases, including next-generation influenza, measles-mumps-rubella-varicella, typhoid, DPT-HiB, hepatitis-B, hepatitis-A, hepatitis-E, Japanese encephalitis, Leishmaniasis, Malaria, Haemorrhagic Congo Fever, Ebola, HPV, and combination vaccines. Cadila Healthcare Limited was founded in 1952 and is based in Ahmedabad, India.
cadila healthcare ltd
(CDH:National Stock Exchange of India)
Satellite Cross Roads
Phone: 91 79 2686 8100
Fax: 91 79 2686 2365www.zyduscadila.com
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for CDH.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact CADILA HEALTHCARE LTD, please visit www.zyduscadila.com. Company data is provided by Capital IQ. Please use this form to report any data issues.